<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Clinical manifestations and diagnosis of bronchiectasis in adults
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Clinical manifestations and diagnosis of bronchiectasis in adults
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Clinical manifestations and diagnosis of bronchiectasis in adults
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alan F Barker, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Talmadge E King, Jr, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul Dieffenbach, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 05, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bronchiectasis shares many clinical features with chronic obstructive pulmonary disease (COPD), including inflamed and easily collapsible airways, obstruction to airflow, and frequent office visits and hospitalizations. The diagnosis is established clinically on the basis of cough on most days with tenacious sputum production, often one or more exacerbations/year, and radiographically by the presence of bronchial airway dilatation on chest computed tomographic (CT) scans [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         The epidemiology, major clinical manifestations, and diagnostic approach to bronchiectasis will be reviewed here. The clinical manifestations and treatment of cystic fibrosis lung disease and the treatment of bronchiectasis are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6369.html" rel="external">
          "Cystic fibrosis: Clinical manifestations of pulmonary disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6372.html" rel="external">
          "Cystic fibrosis: Overview of the treatment of lung disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1435.html" rel="external">
          "Bronchiectasis in adults: Treatment of acute and recurrent exacerbations"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prevalence of bronchiectasis is provided by independent analyses of International Classification of Diseases (ICD) codes from two large and different United States databases [
         <a href="#rid2">
          2
         </a>
         ]. A survey of the United States Medicare population (2012 to 2014) is unique in that ICD codes for bronchiectasis were only accepted from pulmonary specialists [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An estimated 350,000 to 500,000 adults have bronchiectasis in the United States [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The prevalence of bronchiectasis increases with age with an 8- to 10-fold difference in prevalence after the age of 60 years (300 to 500 per 100,000) as compared to ages &lt;40 to 50 years (40 to 50 per 100,000) [
         <a href="#rid2">
          2
         </a>
         ]. Reports from the United Kingdom and Germany describe similar marked age differences in prevalence [
         <a href="#rid4">
          4,5
         </a>
         ]. The Medicare (age ≥65 years) survey of pulmonary specialty-recorded diagnoses had an annual prevalence of 701 per 100,000 persons [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Another approach yields insight into the frequency of bronchiectasis in individuals with chronic cough. From a general population study in Denmark (14,669 individuals), 4 percent had chronic cough (defined as cough lasting &gt;8 weeks) [
         <a href="#rid6">
          6
         </a>
         ]. The greatest risk factor for chronic cough at the individual level among nonsmokers was bronchiectasis with an odds ratio (OR) 5.0, compared with an OR 2.6 for asthma; among former smokers, the OR for bronchiectasis was 7.1.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bronchiectasis is more common in women.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with bronchiectasis use extensive health care resources (eg, frequent ambulatory visits, antibiotic usage, chest CT, hospitalization), and bronchiectasis-associated health care usage has increased. Hospitalization is a major driver of the economic burden [
         <a href="#rid3">
          3,7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The concomitant presence of chronic obstructive pulmonary disease (COPD) increases the use of health care resources and is associated with poorer health [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In underserved populations, including people living in Alaska, Oceania, and parts of India, bronchiectasis is more prevalent, affects individuals at a younger age, and is associated with decreased survival [
         <a href="#rid8">
          8,9
         </a>
         ]. Social and environmental factors undoubtedly play a role, including smoke exposure, limited access to medical care, and delayed use of antibacterial agents for exacerbations.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          PATHOPHYSIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Induction of bronchiectasis requires two factors  (
         <a class="graphic graphic_table graphicRef56821 graphicRef69598 graphicRef81561" href="/z/d/graphic/56821.html" rel="external">
          table 1A-C
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An infectious insult
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Impaired drainage, airway obstruction, or a defect in host defense
        </p>
        <p>
        </p>
        <p>
         The ensuing host response, immune effector cells (predominantly neutrophils), neutrophilic proteases (elastase), reactive oxygen intermediates (eg, hydrogen peroxide [H
         <sub>
          2
         </sub>
         O
         <sub>
          2
         </sub>
         ]), and inflammatory cytokines, creates transmural inflammation, mucosal edema, cratering, ulceration, and neovascularization in the airways [
         <a href="#rid10">
          10
         </a>
         ]. The following factors may contribute to the pathophysiology of bronchiectasis:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Effects of neutrophils and neutrophil elastase
         </strong>
         – Progressive airway destruction in bronchiectasis may be related in part to an abundance of airway neutrophils and unopposed activity of neutrophil elastase. Blood and airway neutrophils in stable bronchiectasis subjects compared with healthy controls have increased viability (reduced apoptosis), reduced phagocytosis, increased release of myeloperoxidase, and impaired bacterial killing (of
         <em>
          Pseudomonas
         </em>
         ) [
         <a href="#rid11">
          11
         </a>
         ]. Pregnancy zone protein (PZP), an intracellular neutrophil protein, has been identified in sputum of bronchiectasis patients and correlates with exacerbations, worsening of symptoms, and the presence of
         <em>
          Pseudomonas aeruginosa
         </em>
         [
         <a href="#rid12">
          12
         </a>
         ]. Neutrophil extracellular traps (NETs) are extracellular complexes of deoxyribonucleic acid (DNA) fibers containing histone, elastase, PZP, and other inflammatory mediators that are formed as part of a process of neutrophil cell death. NETs trap and kill pathogens, such as bacteria, but may also contribute to the destruction of the major bronchi and bronchiole walls and permanent and abnormal dilation associated with neutrophilic inflammation. NET levels in sputum rise with acute infection and are reduced after intravenous antibiotics for exacerbations (but less so for
         <em>
          Pseudomonas
         </em>
         as a pathogen) and after a year of low-dose macrolide prophylaxis for exacerbations [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Physical properties of sputum/mucus
         </strong>
         – The physical properties of sputum differ among patients with cystic fibrosis (CF), those with non-CF bronchiectasis, and healthy controls. Airway mucus from patients with bronchiectasis is more tenacious and concentrated than that of healthy controls, due to higher concentrations of DNA, mucin (MUC5B predominant), and other solids [
         <a href="#rid14">
          14
         </a>
         ]. In physicochemical studies, sputum from Alaska Native children, who have a higher prevalence of bronchiectasis, was less elastic and viscous and had higher transportability than banked sputum of patients with CF and chronic bronchitis [
         <a href="#rid15">
          15
         </a>
         ]. There is accumulating evidence that bronchiectasis begins in or is worsened by different and tenacious mucins in bronchioles [
         <a href="#rid16">
          16
         </a>
         ]. These differences may help explain divergent responses to bronchial hygiene measures. (See
         <a class="medical medical_review" href="/z/d/html/129310.html" rel="external">
          "Bronchiectasis in adults: Maintaining lung health", section on 'Airway clearance therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Atopy as driver of inflammation
         </strong>
         – The presence of atopy conveys a worse clinical course in individuals with chronic obstructive pulmonary disease (COPD) and asthma. In a study of 238 patients with bronchiectasis (excluding allergic bronchopulmonary aspergillosis [ABPA] as etiology) from Scotland, Malaysia, and Singapore, the presence of multiple positive skin prick tests or specific serum immunoglobulin E (IgE) tests was associated with reduced pulmonary function and worse scores on the Bronchiectasis Severity Index [
         <a href="#rid17">
          17
         </a>
         ]. The comparator group for atopy was allergic rhinitis patients with negative CT scans for bronchiectasis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Heterozygous variants of the cystic fibrosis transmembrane regulator (CFTR)
         </strong>
         – Among patients with diffuse bronchiectasis and negative sweat chloride testing, a heterozygous variant of the
         <em>
          CFTR
         </em>
         gene may contribute to the development of bronchiectasis through dysfunction of the airway sodium and chloride channels [
         <a href="#rid18">
          18
         </a>
         ]. This hypothesis was examined in a study that assessed nasal transepithelial potential difference in patients with diffuse bronchiectasis, a normal sweat chloride, and either a normal
         <em>
          CFTR
         </em>
         genotype, or one or two
         <em>
          CFTR
         </em>
         mutations (eg, a loss of function mutation on one chromosome and a mild mutation on the other), and compared the results with those in normal subjects and patients with known CF [
         <a href="#rid18">
          18
         </a>
         ]. The nasal potential difference test reflects the function of sodium and chloride channels in the airway epithelium. An abnormal nasal electrophysiologic phenotype, intermediate between normal and CF values, was identified in patients with diffuse bronchiectasis and one
         <em>
          CFTR
         </em>
         mutation, suggesting that the presence of a single
         <em>
          CFTR
         </em>
         mutation may play a role in the development of diffuse bronchiectasis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Vitamin D deficiency
         </strong>
         – A potential role of vitamin D deficiency in the vicious cycle of recurrent exacerbations of bronchiectasis was examined in an observational study of 402 patients with bronchiectasis, who were followed for three years [
         <a href="#rid19">
          19
         </a>
         ]. At baseline, 50 percent were vitamin D deficient (25 hydroxy-vitamin D levels &lt;25 nmol/L), and another 43 percent were insufficient (25 hydroxy-vitamin D &lt;75 nmol/L). The vitamin D-deficient patients (compared with the insufficient and sufficient patients) were more likely to have sputum colonization with bacteria including
         <em>
          Pseudomonas
         </em>
         , more frequent exacerbations (including those needing hospitalization), worse respiratory symptoms as assessed by standard questionnaires, and increased sputum markers of neutrophil inflammation. It is not known whether this association reflects an effect of vitamin D on innate immunity or reduced outdoor physical activity due to more severe disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Common variable immunodeficiency (CVID)
         </strong>
         – Small airway changes have been described before the advanced and destructive manifestations of bronchiectasis become apparent in patients with CVID. As an example, inspiratory and expiratory high-resolution computed tomography (HRCT) scans were performed on 54 children ages 6 to 18 years with CVID in a stable state [
         <a href="#rid20">
          20
         </a>
         ]. The most common abnormality was expiratory air trapping (mosaic attenuation), which was seen in 71 to 80 percent and was the only abnormality in 9 to 15 percent. The presence of air trapping on expiratory, but not inspiratory, views suggests that airway inflammatory changes are the cause and raises the possibility that these changes are reversible. (See
         <a class="medical medical_review" href="/z/d/html/16132.html" rel="external">
          "Common variable immunodeficiency in children", section on 'Pulmonary manifestations'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3928.html" rel="external">
          "Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults", section on 'Pulmonary disease'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          ETIOLOGIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are numerous etiologies that can induce or contribute to the pathophysiologic processes that result in bronchiectasis  (
         <a class="graphic graphic_table graphicRef56821 graphicRef69598 graphicRef81561" href="/z/d/graphic/56821.html" rel="external">
          table 1A-C
         </a>
         ) [
         <a href="#rid21">
          21-23
         </a>
         ]. They include airway obstruction (eg, foreign body aspiration), defective host defenses, cystic fibrosis (CF), Young syndrome, rheumatic and systemic diseases, primary ciliary dyskinesia, pulmonary infections, and allergic bronchopulmonary aspergillosis (ABPA). The frequency of the different etiologies varies with the geographic location and referral population, as shown in the following studies:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a North American referral center population, a comprehensive evaluation of 112 patients with bronchiectasis confirmed on chest CT identified a specific etiology in 93 percent [
         <a href="#rid21">
          21
         </a>
         ]. The most common etiologies were rheumatic disease (eg, rheumatoid arthritis, Sjögren's disease, Crohn disease), ABPA, immunodeficiency, hematologic malignancy, aspiration, and nontuberculous mycobacterial infection.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A report from the European Bronchiectasis Network (EMBARC) comprising academic medical center databases in Europe identified an underlying cause of bronchiectasis in 60 percent of nearly 17,000 patients, including postinfection (21 percent; includes previous pneumonia, remote childhood infections, and pertussis), chronic obstructive pulmonary disease (COPD; 8.1 percent), mycobacterial disease (5.9 percent), rheumatic disorders (4.8 percent), and immunodeficiency (4.1 percent) [
         <a href="#rid24">
          24
         </a>
         ]. Testing that followed British Thoracic Society guidelines [
         <a href="#rid25">
          25
         </a>
         ] identified an etiology that would potentially lead to genetic testing (eg, alpha-1 antitrypsin deficiency) or a change in management (eg, replacement therapy for immunodeficiency, specific treatment of ABPA, prevention of aspiration, treatment of focal obstruction, or aggressive bronchial hygiene in ciliary dyskinesia) in 13 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An underlying etiology is often identified in children and adolescents. In a systematic review of 989 patients with non-CF bronchiectasis, ages 21 years and younger, an etiology was identified in 623 (63 percent) [
         <a href="#rid26">
          26
         </a>
         ]. Of greater importance, 35 percent of these patients had immunodeficiency (primary and secondary), aspiration/foreign body, or ciliary dyskinesia, conditions in which specific management strategies may improve the outcome.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Airway obstruction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Focal airway obstruction can be caused by foreign body aspiration, an intraluminal obstructing lesion such as a carcinoid tumor, or extraluminal compression from encroaching lymph nodes [
         <a href="#rid27">
          27
         </a>
         ]. A case report demonstrated focal bronchiectasis 3.5 years after placement of lung volume reduction coils for emphysema [
         <a href="#rid28">
          28
         </a>
         ]. It is important to identify the presence of airway obstruction because surgical resection is often curative.
        </p>
        <p>
         Bronchiectasis that results from foreign body aspiration generally occurs in the right lung and in the lower lobes or the posterior segments of the upper lobes. As an example, toddlers (ages one to three years) may aspirate seeds, popcorn, or unchewed food. An episode of choking, coughing, or unexplained wheezing or hemoptysis should raise the suspicion of a foreign body [
         <a href="#rid29">
          29
         </a>
         ]. A retrospective study found that, among children with greater than one month of respiratory symptoms and middle lobe or lingula abnormalities on chest radiograph, an early and aggressive strategy of chest CT and bronchoscopy with cultures led to interventions (eg, foreign body removal, infection treatment) that produced favorable outcomes, including reduced bronchiectasis [
         <a href="#rid30">
          30
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6382.html" rel="external">
          "Airway foreign bodies in children"
         </a>
         .)
        </p>
        <p>
         In adults, particulate aspiration is typically associated with an altered state of consciousness (due to stroke, seizures, intoxication, or emergent general anesthesia). The foreign body is often unchewed food or part of a tooth or crown. A postobstructive pneumonia may follow the aspiration event, often resulting in incomplete resolution and predisposition to subsequent lung abscess. Delayed or ineffective therapy and poor nutrition may contribute to prolonged pneumonitis with resultant focal bronchiectasis  (
         <a class="graphic graphic_figure graphicRef58341" href="/z/d/graphic/58341.html" rel="external">
          figure 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/4387.html" rel="external">
          "Airway foreign bodies in adults"
         </a>
         .)
        </p>
        <p>
         Esophageal reflux contributes to asthma and interstitial lung disease. The same concern or association applies to bronchiectasis [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H430555831">
         <span class="h2">
          Tracheobronchomalacia and tracheobronchomegaly
         </span>
         <span class="headingEndMark">
          —
         </span>
         Anatomic defects of the airways, such as tracheomalacia, deficiency of cartilage in fourth to sixth order bronchi (Williams-Campbell syndrome)  (
         <a class="graphic graphic_diagnosticimage graphicRef98312" href="/z/d/graphic/98312.html" rel="external">
          image 1
         </a>
         ), bronchomalacia, and tracheobronchomegaly, can lead to bronchiectasis via deficient clearance of respiratory secretions and recurrent infections [
         <a href="#rid32">
          32
         </a>
         ]. While the airways appear dilated on imaging studies, the deficient cartilage support results in airway collapse during forced exhalation. Chest CT with expiratory views will show proximal airway collapse and narrowing. Tracheomalacia, bronchomalacia, and tracheobronchomalacia refer to diffuse or segmental weakness of the trachea and/or mainstem bronchi and are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4406.html" rel="external">
          "Tracheomalacia in adults: Clinical features and diagnostic evaluation"
         </a>
         .)
        </p>
        <p>
         Tracheobronchomegaly (eg, Mounier-Kuhn syndrome) can be diagnosed when the diameter of the trachea (measured 2 cm above the main carina), right mainstem bronchus, and left mainstem bronchus exceed a diameter two standard deviations above normal [
         <a href="#rid33">
          33
         </a>
         ]. As a general rule, tracheomegaly is likely present when the lower trachea is wider than the vertebral column at that level. More precisely, airway diameters exceeding the following are abnormal: trachea &gt;3 cm, a right mainstem bronchus &gt;2.5 cm, and a left mainstem bronchus &gt;2 cm. (See
         <a class="medical medical_review" href="/z/d/html/6984.html" rel="external">
          "Radiology of the trachea", section on 'Tracheobronchomegaly'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Defective host defenses
         </span>
         <span class="headingEndMark">
          —
         </span>
         Impairment in host defenses may be local, as with ciliary dyskinesia [
         <a href="#rid34">
          34
         </a>
         ], or systemic, as with hypogammaglobulinemia, or prolonged immunosuppression (eg, in transplant patients and patients with rheumatic disorders on biologic disease-modifying agents) [
         <a href="#rid35">
          35-37
         </a>
         ]. The mechanism of bronchiectasis is likely bronchial wall injury from repeated infections [
         <a href="#rid35">
          35
         </a>
         ]. (See
         <a class="local">
          'Primary ciliary dyskinesia'
         </a>
         below.)
        </p>
        <p>
         Patients with hypogammaglobulinemia (eg, x-linked) usually present in childhood with repeated sinopulmonary infections; however, middle-aged adults have been identified with few or no recognized previous respiratory infections [
         <a href="#rid38">
          38,39
         </a>
         ]. Hypogammaglobulinemia may also be associated with thymoma [
         <a href="#rid40">
          40
         </a>
         ]. Immunoglobulin quantitation is included in the diagnostic evaluation of the patient with bronchiectasis, since gamma globulin replacement can diminish or prevent further respiratory tract infections and lung damage. (See
         <a class="medical medical_review" href="/z/d/html/3928.html" rel="external">
          "Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults", section on 'Evaluation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3952.html" rel="external">
          "Treatment and prognosis of common variable immunodeficiency", section on 'Immune globulin replacement therapy'
         </a>
         .)
        </p>
        <p>
         Isolated IgG subclass deficiency (in the presence of normal or near-normal levels of total IgG) as a cause of bronchiectasis is controversial due to variable ranges of values even in healthy individuals. In a multicenter study of young children from the Netherlands, 49 with IgG subclass deficiency (mainly IgG2) and reduced antibody response to a polysaccharide antigen were identified and followed [
         <a href="#rid41">
          41
         </a>
         ]. At least five of the children (10 percent) had bronchiectasis at an average age of seven years. To help determine whether a low IgG subclass represents immunodeficiency, a challenge with common humoral bacterial antigens (eg,
         <em>
          Haemophilus influenzae
         </em>
         vaccine or pneumococcal vaccine), followed six weeks later by measurement of antibody titers, can be performed [
         <a href="#rid42">
          42,43
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3914.html" rel="external">
          "Primary humoral immunodeficiencies: An overview"
         </a>
         .)
        </p>
        <p>
         Milder cases of autosomal recessive chronic granulomatous disease may present in adulthood. Extrapulmonary infections such as cellulitis, cutaneous abscesses, lymphadenitis, and osteomyelitis are common in these patients. The majority of infections are due to
         <em>
          Staphylococcus aureus
         </em>
         ,
         <em>
          Burkholderia
         </em>
         (formerly
         <em>
          Pseudomonas
         </em>
         )
         <em>
          cepacia
         </em>
         ,
         <em>
          Serratia marcescens
         </em>
         ,
         <em>
          Nocardia
         </em>
         , and
         <em>
          Aspergillus
         </em>
         . (See
         <a class="medical medical_review" href="/z/d/html/3925.html" rel="external">
          "Chronic granulomatous disease: Pathogenesis, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Cystic fibrosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinical disease requires pathogenic mutations in both copies of the cystic fibrosis transmembrane conductance regulator (
         <em>
          CFTR
         </em>
         ) gene. Although formerly considered a disease of childhood, up to 7 percent of patients with cystic fibrosis (CF) are diagnosed at age 18 years or older [
         <a href="#rid44">
          44
         </a>
         ]. Sinusitis and bronchiectasis are the major respiratory manifestations of CF, and the latter may be the sole feature of CF in adults. (See
         <a class="medical medical_review" href="/z/d/html/6367.html" rel="external">
          "Cystic fibrosis: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
         Clues suggesting the presence of this disorder include upper lobe radiographic involvement and sputum cultures showing mucoid
         <em>
          P. aeruginosa
         </em>
         [
         <a href="#rid45">
          45
         </a>
         ]. When CF is diagnosed after the age of 20 years, homozygosity at the delta F508 locus in the
         <em>
          CFTR
         </em>
         gene is less common than in children and non-delta F508 mutations are more common. (See
         <a class="medical medical_review" href="/z/d/html/6368.html" rel="external">
          "Cystic fibrosis: Genetics and pathogenesis"
         </a>
         .)
        </p>
        <p>
         A positive sputum culture for mucoid
         <em>
          P. aeruginosa
         </em>
         in the year of diagnosis is more common in adults than children with CF, while a positive culture for nonmucoid
         <em>
          P. aeruginosa
         </em>
         is more common in children [
         <a href="#rid45">
          45
         </a>
         ]. Adults also have increased colonization with nontuberculous mycobacteria [
         <a href="#rid45">
          45-47
         </a>
         ]. Pancreatic insufficiency and diabetes mellitus are less common when CF is discovered after age 20 years than before.
        </p>
        <p>
         The diagnosis of CF can usually be established by demonstrating an elevated sweat chloride concentration (≥60 mmol/L; values of 30 to 60 require additional testing), which is performed at specialized centers [
         <a href="#rid44">
          44,45
         </a>
         ]. Patients who present with CF as adults may have intermediate or normal sweat chloride results. Screening for mutations in the
         <em>
          CFTR
         </em>
         gene may be required to confirm the diagnosis [
         <a href="#rid44">
          44
         </a>
         ]. Measurement of the potential difference across the nasal epithelium, available in specialized centers, is sometimes used to corroborate the diagnosis [
         <a href="#rid18">
          18,45
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6367.html" rel="external">
          "Cystic fibrosis: Clinical manifestations and diagnosis", section on 'Sweat chloride'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6367.html" rel="external">
          "Cystic fibrosis: Clinical manifestations and diagnosis", section on 'Molecular diagnosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6367.html" rel="external">
          "Cystic fibrosis: Clinical manifestations and diagnosis", section on 'Nasal potential difference measurements'
         </a>
         .)
        </p>
        <p>
         Individuals with a single pathogenic mutation
         <em>
          CFTR
         </em>
         Phe508del (carriers) may be at increased risk of pulmonary disease in adulthood (eg, bronchiectasis, chronic bronchitis), depending on environmental exposures (eg, cigarette smoking) and other genetic risk factors (eg, variants in epithelial sodium channel genes) [
         <a href="#rid6">
          6,48,49
         </a>
         ]. Individuals with bronchiectasis and a single Phe508del mutation are considered to have a CFTR-related disorder, which is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6367.html" rel="external">
          "Cystic fibrosis: Clinical manifestations and diagnosis", section on 'CFTR-related disorder'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Young syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Young syndrome describes patients with bronchiectasis, sinusitis, and obstructive azoospermia who have no evidence of CF. As the frequency of this diagnosis has declined to almost nonexistent, some experts have suggested that exposure to mercury in childhood may have been a cause of Young syndrome in men born before 1955 [
         <a href="#rid50">
          50
         </a>
         ]. Another possibility is that some cases attributed to Young syndrome are actually cases of primary ciliary dyskinesia (PCD). Now that better diagnostic methods are available, these cases can be correctly identified as forms of PCD. (See
         <a class="medical medical_review" href="/z/d/html/4338.html" rel="external">
          "Primary ciliary dyskinesia (immotile-cilia syndrome)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7473.html" rel="external">
          "Causes of male infertility", section on 'Sperm transport disorders'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Rheumatic and other systemic diseases
         </span>
         <span class="headingEndMark">
          —
         </span>
         Two rheumatic diseases, rheumatoid arthritis (RA) [
         <a href="#rid51">
          51-53
         </a>
         ] and Sjögren's disease [
         <a href="#rid54">
          54
         </a>
         ], can be complicated by bronchiectasis. Arthropathy and sicca features are usually advanced when bronchiectasis becomes apparent. In some cases, however, bronchiectasis occurs before the rheumatic disease. The association of RA and bronchiectasis is accompanied by a higher mortality than other bronchiectasis associations except COPD [
         <a href="#rid55">
          55
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4380.html" rel="external">
          "Overview of pleuropulmonary diseases associated with rheumatoid arthritis", section on 'Bronchiectasis'
         </a>
         .)
        </p>
        <p>
         The mechanism underlying bronchiectasis in patients with RA and Sjögren's disease is not known. In a family-based association study, the frequency of an abnormal CF gene (
         <em>
          CFTR
         </em>
         ) allele was increased in patients with bronchiectasis and RA relative to patients with RA but without bronchiectasis and normal controls [
         <a href="#rid56">
          56
         </a>
         ]. (See
         <a class="local">
          'Pathophysiology'
         </a>
         above.)
        </p>
        <p>
         Bronchiectasis has been noted in association with other systemic diseases, such as inflammatory bowel disease, more frequently in ulcerative colitis than in Crohn disease, and the yellow nail syndrome [
         <a href="#rid57">
          57,58
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4344.html" rel="external">
          "Pulmonary complications of inflammatory bowel disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Primary ciliary dyskinesia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Primary ciliary dyskinesia was originally described in the respiratory tract and sperm of patients with Kartagener syndrome (situs inversus, sinusitis, bronchiectasis), but situs inversus is present in only half of patients with dyskinetic cilia and related poor mucociliary clearance, repeated sinopulmonary infections, and subsequent bronchiectasis [
         <a href="#rid34">
          34,59,60
         </a>
         ]. Nasal nitric oxide analysis, although not widely available, is a useful screening test for PCD; low levels (eg, 77 nL/minute) are consistent with PCD [
         <a href="#rid61">
          61
         </a>
         ]. An extended panel genetic testing (&gt;12 genes) is available for the most frequently associated genetic abnormalities [
         <a href="#rid62">
          62,63
         </a>
         ]. An epithelial (nasal or bronchial) brush or biopsy may be useful but requires labor-intensive testing to assess ciliary motion and ultrastructure. The diagnosis and management of PCD are described separately. (See
         <a class="medical medical_review" href="/z/d/html/4338.html" rel="external">
          "Primary ciliary dyskinesia (immotile-cilia syndrome)", section on 'Nasal nitric oxide'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4338.html" rel="external">
          "Primary ciliary dyskinesia (immotile-cilia syndrome)", section on 'Genetic testing'
         </a>
         .)
        </p>
        <p>
         Further evidence of the relationship between bronchiectasis and dyskinetic cilia comes from patients with autosomal dominant polycystic kidney disease (ADPKD), a disease in which renal cysts develop because of defective cilia and ciliary protein expression (polycystin-1 and polycystin-2) [
         <a href="#rid64">
          64,65
         </a>
         ]. Immunostaining of lung tissue from non-ADPKD patients reveals that the motile cilia of airway epithelial cells express polycystin-1, suggesting that absent polycystin-1 in patients with ADPKD might be a risk factor for airway damage [
         <a href="#rid64">
          64
         </a>
         ]. In a retrospective review of chest CT scans, 34 out of 92 patients with ADPKD had bronchiectasis (37 percent) compared to 12 out of 93 patients with non-ADPKD chronic renal disease (13 percent), a difference that was statistically significant [
         <a href="#rid64">
          64
         </a>
         ]. In autopsy examinations, the lungs from one of five patients with ADPKD had histologic evidence of bronchiectasis.
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Alpha-1 antitrypsin deficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         Emphysema is the main lung disease recognized in alpha-1 antitrypsin deficiency. However, a review of the clinical manifestations and chest CT scans of 74 patients with alpha-1 antitrypsin deficiency found that 70 had radiographic abnormalities suggestive of bronchiectasis (95 percent) and 20 had regular sputum production (27 percent) [
         <a href="#rid66">
          66
         </a>
         ]. These observations support current guidelines that recommend alpha-1 testing in patients with bronchiectasis and no other evident etiology [
         <a href="#rid67">
          67
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1464.html" rel="external">
          "Clinical manifestations, diagnosis, and natural history of alpha-1 antitrypsin deficiency"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Pulmonary infections
         </span>
         <span class="headingEndMark">
          —
         </span>
         A spectrum of bacterial, mycobacterial, atypical bacterial, and viral lung infections have been associated with the development of bronchiectasis.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Childhood infections
         </strong>
         – Childhood lung infections (eg, bacterial, viral, and mycoplasma pneumonia and protracted bacterial bronchitis) have been implicated in the pathogenesis of bronchiectasis [
         <a href="#rid68">
          68
         </a>
         ]. In a case series of 38 children with mycoplasma pneumonia, eight children had evidence of bronchiectasis on high-resolution computed tomography (HRCT) obtained one to two years later [
         <a href="#rid68">
          68
         </a>
         ]. In a cohort study, 161 children with protracted bacterial bronchitis (history of &gt;4 weeks of wet cough, treatment with
         <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">
          amoxicillin
         </a>
         for two weeks, and no evidence for other causes of cough) were followed for two years, and 8 percent developed bronchiectasis [
         <a href="#rid69">
          69
         </a>
         ]. Risk factors were infection by
         <em>
          Haemophilus influenzae
         </em>
         and recurrent episodes of bacterial bronchitis. Childhood whooping cough (pertussis) is largely of historical interest [
         <a href="#rid68">
          68
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8045.html" rel="external">
          "Pertussis infection in adolescents and adults: Clinical manifestations and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5995.html" rel="external">
          "Pertussis infection in infants and children: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adult infections
         </strong>
         – Virulent pneumonias in adults due to viruses and bacteria (such as
         <em>
          S. aureus
         </em>
         ) has been recognized as precursors to bronchiectasis [
         <a href="#rid70">
          70
         </a>
         ]. Advanced bronchiectasis has been reported after widespread severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pneumonia [
         <a href="#rid71">
          71-73
         </a>
         ]. One report mentions that
         <em>
          S. aureus
         </em>
         may have been a copathogen similar to what has been known regarding the association of
         <em>
          S. aureus
         </em>
         with influenza virus [
         <a href="#rid71">
          71
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6990.html" rel="external">
          "Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults", section on 'S. aureus'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mycobacterial infections
         </strong>
         – In addition to direct tissue injury, a sequela of virulent infections (such as tuberculosis) may include enlarged and caseous lymph nodes around bronchi or damaged airways that predispose to bacterial colonization [
         <a href="#rid74">
          74,75
         </a>
         ]. In a Korean study, 9 percent of 1409 individuals who underwent chest CT for health screening (mostly for lung cancer) had bronchiectasis; a previous history of tuberculosis was significantly associated with bronchiectasis [
         <a href="#rid74">
          74
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Nontuberculous mycobacteria (NTM) have traditionally been considered a secondary pathogen in an immunocompromised host (acquired immunodeficiency syndrome [AIDS]) or in a previously damaged lung (bullous emphysema). However, apparently healthy individuals (primarily nonsmoking women over the age of 50 years) may develop bronchiectasis due to primary NTM infection. Similar to a sputum smear showing acid-fast bacilli and a culture confirming the presence of NTM, a CT scan of the chest is relatively specific, showing small irregular nodules, often in the middle lobe or lingula [
         <a href="#rid76">
          76-78
         </a>
         ]. Patients with bronchiectasis and NTM infection are more likely to have aspergillus-related lung disease (including ABPA) than patients with bronchiectasis who do not have NTM infection [
         <a href="#rid79">
          79
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <em>
          Mycobacterium avium
         </em>
         complex (MAC) are the most frequently identified NTMs. Evidence of the pathogenicity of MAC comes from a surgical series of nine patients with positive sputum cultures for MAC [
         <a href="#rid80">
          80
         </a>
         ]. Examination of resected lung tissues revealed MAC, bronchiectasis, and granulomata. (See
         <a class="medical medical_review" href="/z/d/html/5344.html" rel="external">
          "Epidemiology of nontuberculous mycobacterial infections"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5346.html" rel="external">
          "Diagnosis of nontuberculous mycobacterial infections of the lungs"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5341.html" rel="external">
          "Treatment of
          <i>
           Mycobacterium avium
          </i>
          complex pulmonary infection in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           Nocardia
          </em>
         </strong>
         –
         <em>
          Nocardia
         </em>
         may be a contributory pathogen in bronchiectasis. In a retrospective review, Duke University investigators identified 183 patients with positive cultures for
         <em>
          Nocardia
         </em>
         species between 1996 and 2013 [
         <a href="#rid81">
          81
         </a>
         ]. Of these, 40 (22 percent) had bronchiectasis, and the incidence of
         <em>
          Nocardia
         </em>
         appeared to increase over time.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Allergic bronchopulmonary aspergillosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Allergic bronchopulmonary aspergillosis (ABPA) should be suspected in patients with a long history of asthma that is resistant to bronchodilator therapy and associated with a cough often productive of sputum that is mucopurulent or contains mucous plugs. ABPA may also be seen in COPD, particularly when there are features of asthma [
         <a href="#rid82">
          82
         </a>
         ]. Sputum cultures may be positive for
         <em>
          Aspergillus
         </em>
         species. Chest CT scans show peripheral and central airway bronchiectasis, which is unusual in patients with bronchiectasis caused by other disorders [
         <a href="#rid83">
          83
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2419.html" rel="external">
          "Clinical manifestations and diagnosis of allergic bronchopulmonary aspergillosis"
         </a>
         .)
        </p>
        <p>
         ABPA probably represents a hyperimmune reaction to the
         <em>
          Aspergillus
         </em>
         organism, rather than a true infection, and is characterized by an exaggerated T helper cell response. Immunologic features of ABPA include blood eosinophilia, very high plasma IgE levels, and precipitating and specific antibodies to
         <em>
          Aspergillus
         </em>
         [
         <a href="#rid83">
          83
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1491365506">
         <span class="h2">
          Asthma
         </span>
         <span class="headingEndMark">
          —
         </span>
         An interrelationship between asthma and bronchiectasis is suspected, even in the absence of ABPA. Patients with bronchiectasis may wheeze and have bronchial hyperresponsiveness without meeting the criteria for asthma, but there may be a specific phenotype of bronchiectasis with asthma (similar to the concept of asthma-COPD overlap) that represents an independent risk factor for frequent exacerbations. In a database survey, asthma (diagnosed based on clinical characteristics and reversible airflow limitation per international guidelines) was an independent risk factor for bronchiectasis exacerbations [
         <a href="#rid84">
          84
         </a>
         ].
        </p>
        <p>
         Bronchial thermoplasty (BT), a treatment for severe asthma, was associated with a 7 percent incidence of new bronchiectasis on chest CT (not seen before BT), based on data from a multicenter registry of patients enrolled in large clinical trials of BT and followed for 10 or more years [
         <a href="#rid85">
          85
         </a>
         ]. This observation is intriguing because one of the physiologic effects of bronchial thermoplasty is airway dilation, a chest CT diagnostic criterion for bronchiectasis. It is also unknown how many of the asthmatic patients might have developed bronchiectasis during this lengthy follow-up independent of the procedure. (See
         <a class="medical medical_review" href="/z/d/html/543.html" rel="external">
          "Asthma in adolescents and adults: Evaluation and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/551.html" rel="external">
          "Treatment of severe asthma in adolescents and adults", section on 'Bronchial thermoplasty'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Cigarette smoking and COPD
         </span>
         <span class="headingEndMark">
          —
         </span>
         A causal role for cigarette smoking in bronchiectasis has not been demonstrated. However, cigarette smoking, the presence of chronic obstructive pulmonary disease (COPD), and repeated infections or exacerbations may worsen pulmonary function and accelerate the progression of disease that is already present [
         <a href="#rid86">
          86-91
         </a>
         ]. In one observational study of current and former smokers with a &gt;20 pack-year history, those with possible bronchiectasis (cough, phlegm, dyspnea, or frequent exacerbations plus a quantitative CT measure of dilated airways) demonstrated increased mortality at 10 years compared with those without these findings even after adjustment for demographics, smoking history, spirometry, and CT measures of emphysema [
         <a href="#rid92">
          92
         </a>
         ].
        </p>
        <p>
         A quantitative CT study that compared smokers with bronchiectasis (based on imaging) to healthy nonsmokers has raised the hypothesis that an increased bronchus-to-artery ratio in smokers may be due to arterial constriction (hypoxemia) rather than bronchial dilation [
         <a href="#rid93">
          93
         </a>
         ]. In this study, bronchial and adjacent arterial diameters were measured on HRCT images of "bronchiectatic" and normal airways. The arterial diameters in the "bronchiectatic" areas were smaller than those in nonbronchiectatic areas.
        </p>
        <p class="headingAnchor" id="H5990869">
         <span class="h1">
          CLINICAL FEATURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The classic clinical manifestations of bronchiectasis are cough most days of the week, production of mucopurulent and tenacious sputum most days of the week for months to years, and a history of exacerbations [
         <a href="#rid1">
          1,94,95
         </a>
         ]. The older literature also described "dry bronchiectasis" with episodic hemoptysis and no sputum production, but this presentation is less common.
        </p>
        <p>
         Other, less specific complaints include dyspnea, wheezing, and pleuritic chest pain. Patients often report frequent bouts of "bronchitis" requiring therapy with repeated courses of antibiotics. There is generally a past history of repeated respiratory tract infections over several years, although a single episode of severe bacterial pneumonia, pertussis, or tuberculosis can also result in bronchiectasis. (See
         <a class="local">
          'Etiologies'
         </a>
         above.)
        </p>
        <p>
         In a retrospective chart review of 103 patients with bronchiectasis who presented to a referral center, the following clinical findings were documented [
         <a href="#rid96">
          96
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Symptoms
         </strong>
         – cough (98 percent of patients), daily sputum production (78 percent), dyspnea (62 percent), rhinosinusitis (73 percent), hemoptysis (27 percent), and recurrent pleurisy (20 percent)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Physical findings
         </strong>
         – crackles (75 percent) and wheezing (22 percent) were common, with digital clubbing occurring in only 2 percent of patients
        </p>
        <p>
        </p>
        <p>
         Several validated questionnaire instruments encompassing key respiratory issues and general health quality have been useful as outcome measures in clinical research. They include new ones specifically for bronchiectasis (eg, Quality Of Life-Bronchiectasis, Bronchiectasis Health Questionnaire) or adapted from chronic obstructive pulmonary disease (COPD; eg, St. George Respiratory Questionnaire [SGRQ], COPD Assessment Test, Leicester Cough Questionnaire) [
         <a href="#rid97">
          97
         </a>
         ]. Experience with the SGRQ is most extensive. The COPD Assessment Test (CAT) is the most facile with fewer questions and can easily be adapted to longitudinal clinical practice [
         <a href="#rid98">
          98-100
         </a>
         ].
        </p>
        <p>
         Although respiratory complaints are prominent, other symptoms can be annoying and distressing. Fatigue was noted in 43 percent of 117 bronchiectasis patients using a validated fatigue impact scale. The presence of fatigue correlated with lower forced expiratory volume in one second (FEV
         <sub>
          1
         </sub>
         ) values, but not the presence of
         <em>
          P. aeruginosa
         </em>
         in sputum [
         <a href="#rid101">
          101
         </a>
         ]. Seventy-five women attending a respiratory clinic were evaluated for urinary incontinence and its effect on their qualities of life [
         <a href="#rid102">
          102
         </a>
         ]. The prevalence of urinary incontinence in the patients with bronchiectasis was 47 percent, compared to an estimated prevalence of 10 to 12 percent in the general population. Many of these patients were reluctant to discuss such complaints. Identification and treatment of urinary incontinence can improve or relieve this symptom [
         <a href="#rid103">
          103
         </a>
         ].
        </p>
        <p>
         Among patients with bronchiectasis, a reduced sense of smell is common. In a study of 91 patients with bronchiectasis, a significant reduction in sense of smell was noted in patients with a history of chronic rhinosinusitis (with or without associated nasal polyps) and/or primary humoral immunodeficiency [
         <a href="#rid104">
          104
         </a>
         ]. Reduced bone mineral density, osteopenia, and even osteoporosis have been found in patients with non-cystic fibrosis (CF) bronchiectasis [
         <a href="#rid105">
          105
         </a>
         ]. Comparisons were made with retrospective controls. The reduced bone mineral density was particularly noteworthy in the younger (&lt;45 years of age) subjects.
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          DIAGNOSTIC EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of bronchiectasis should be suspected in patients with persistent or recurrent production of mucopurulent or purulent sputum [
         <a href="#rid94">
          94
         </a>
         ]. The purpose of a diagnostic evaluation is radiographic confirmation of the diagnosis, identification of potentially treatable causes and microbiologic pathogens, and functional assessment  (
         <a class="graphic graphic_table graphicRef56821 graphicRef69598 graphicRef81561" href="/z/d/graphic/56821.html" rel="external">
          table 1A-C
         </a>
         ) [
         <a href="#rid25">
          25
         </a>
         ]. The evaluation consists of laboratory testing, radiographic imaging, and pulmonary function testing.
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h2">
          Laboratory tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following studies are typically part of the initial evaluation of a patient with bronchiectasis [
         <a href="#rid106">
          106
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A complete blood count with differential. Elevated blood platelets (&gt;400 x 10
         <sup>
          9
         </sup>
         /L in a stable state) are associated with increased mortality, increased hospitalizations for exacerbations, poor quality of life by questionnaire, and increased severity by the Bronchiectasis Severity Index [
         <a href="#rid107">
          107
         </a>
         ]. Elevated eosinophils may identify an endotype that has treatment implications as seen in asthma and chronic obstructive pulmonary disease (COPD) [
         <a href="#rid108">
          108,109
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/129310.html" rel="external">
          "Bronchiectasis in adults: Maintaining lung health"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Immunoglobulin quantitation to measure the levels of the immunoglobulins IgG, IgM, and IgA. (See
         <a class="medical medical_review" href="/z/d/html/3914.html" rel="external">
          "Primary humoral immunodeficiencies: An overview"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3928.html" rel="external">
          "Clinical manifestations, epidemiology, and diagnosis of common variable immunodeficiency in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Testing for cystic fibrosis (CF): Sweat chloride and/or mutation analysis of the cystic fibrosis transmembrane conductance regulator (
         <em>
          CFTR
         </em>
         ) gene. (See
         <a class="local">
          'Cystic fibrosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sputum smear and culture for bacteria, mycobacteria, and fungi.
        </p>
        <p>
        </p>
        <p>
         Additional tests that are obtained in the appropriate setting may include  (
         <a class="graphic graphic_table graphicRef56821 graphicRef69598 graphicRef81561" href="/z/d/graphic/56821.html" rel="external">
          table 1A-C
         </a>
         ) (see
         <a class="local">
          'Etiologies'
         </a>
         above):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Specific aspergillus IgE and IgG antibodies, total serum IgE level (see
         <a class="local">
          'Allergic bronchopulmonary aspergillosis'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/2419.html" rel="external">
          "Clinical manifestations and diagnosis of allergic bronchopulmonary aspergillosis", section on 'Diagnosis'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         IgG subclass levels (see
         <a class="medical medical_review" href="/z/d/html/3906.html" rel="external">
          "IgG subclass deficiency", section on 'Evaluation'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Antibody titers to pneumococcal serotypes before and four weeks after vaccination with polysaccharide pneumococcal vaccine (see
         <a class="medical medical_review" href="/z/d/html/3929.html" rel="external">
          "Assessing antibody function as part of an immunologic evaluation", section on 'Adults and children over two years'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Alpha-1 antitrypsin level and/or genotype (see
         <a class="local">
          'Alpha-1 antitrypsin deficiency'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rheumatoid factor
        </p>
        <p>
        </p>
        <p>
         Cell counts of induced sputum are being evaluated as a way to identify patients with bronchiectasis. In a retrospective series of patients with stable obstructive airways disease who had a high-resolution computed tomography (HRCT) available for analysis, sputum leukocytosis and neutrophilia were more common in those with radiographic bronchiectasis than those without (mean 48.2 x 10
         <sup>
          6
         </sup>
         versus 12.6 x 10
         <sup>
          6
         </sup>
         cells/gram of sputum and 78.2 versus 64.4 percent neutrophils) [
         <a href="#rid110">
          110
         </a>
         ]. Performing cell counts on induced sputum is labor intensive and would require more study prior to widespread implementation.
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h2">
          Chest radiograph
         </span>
         <span class="headingEndMark">
          —
         </span>
         The chest radiograph is abnormal in most patients with bronchiectasis. Suspicious but nondiagnostic radiographic findings include linear atelectasis, dilated and thickened airways (ie, tram or parallel lines, ring shadows on cross section)  (
         <a class="graphic graphic_diagnosticimage graphicRef75583 graphicRef63795" href="/z/d/graphic/75583.html" rel="external">
          image 2A-B
         </a>
         ), and irregular peripheral opacities that may represent mucopurulent plugs.
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h2">
          Computed tomography
         </span>
         <span class="headingEndMark">
          —
         </span>
         Noncontrast chest CT has become the definitive study to confirm the diagnosis of bronchiectasis. The vast majority of computed tomography (CT) scanners are now multidetector computed tomography (MDCT) scanners, which can obtain thin sections of ≤1 mm (high resolution) with high spatial frequency. MDCT is the preferred imaging modality for bronchiectasis [
         <a href="#rid94">
          94,111
         </a>
         ]. HRCT originally referred to scanners that obtained images of 1 to 1.5 mm collimation slices every 10 mm. (See
         <a class="medical medical_review" href="/z/d/html/6988.html" rel="external">
          "High resolution computed tomography of the lungs"
         </a>
         .)
        </p>
        <p>
         MDCT (or HRCT if MDCT is not available) is indicated in the following settings:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There are suspicious clinical findings but a relatively normal chest radiograph.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The chest radiograph has abnormal findings (eg, persistent consolidative opacity or thickened airways) and bronchiectasis is strongly suspected.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Management decisions must be made that depend upon the extent of bronchiectasis. As an example, mapping of the chest is needed to define suspected abnormal areas and to demonstrate absent or minimal involvement in the rest of the lung if surgical resection is being contemplated.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The presence (or absence) of confounding diseases needs to be defined, such as chronic obstructive lung disease, interstitial lung disease, or malignancy.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h3">
          Features
         </span>
         <span class="headingEndMark">
          —
         </span>
         The major features of bronchiectasis on HRCT or MDCT include [
         <a href="#rid1">
          1,94
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Airway dilatation, which can be detected as parallel (tram) lines or end-on ring shadows  (
         <a class="graphic graphic_diagnosticimage graphicRef73028" href="/z/d/graphic/73028.html" rel="external">
          image 3
         </a>
         ). An airway lumen diameter ≥1.5 times the adjacent vessel (called airway-artery or bronchoarterial ratio) is indicative of cylindrical bronchiectasis. The "signet-ring" sign, which is a classic feature of bronchiectasis, refers to the appearance in cross-section of a dilated, air-filled bronchus that is contiguous with the smaller nodular opacity of a pulmonary artery (the jewel on the ring) [
         <a href="#rid111">
          111
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lack of tapering towards the periphery of the chest in combination with dilatation may be more specific than bronchial dilatation alone because some healthy individuals and patients with asthma may have areas of bronchial dilatation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Airway visibility within 1 cm of a costal pleural surface or touching the mediastinal pleura.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Airways affected by bronchiectasis may contain mucopurulent plugs or debris accompanied by postobstructive air trapping. When small airways are affected, peripheral, irregular, short (2 to 4 mm) linear branching markings are noted and the term "tree-in-bud pattern" is applicable  (
         <a class="graphic graphic_diagnosticimage graphicRef52831" href="/z/d/graphic/52831.html" rel="external">
          image 4
         </a>
         ). Although tree-in-bud may acutely reflect aspiration and/or bacterial infection, persistence of findings is suspicious for bronchiectasis distinctly associated with nontuberculous mycobacteria (NTM) infection [
         <a href="#rid112">
          112
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cysts off the bronchial wall are a feature of more destructive bronchiectasis  (
         <a class="graphic graphic_diagnosticimage graphicRef60935" href="/z/d/graphic/60935.html" rel="external">
          image 5
         </a>
         ). In heavily involved areas, the cysts are clustered to appear like grapes (cystic bronchiectasis)  (
         <a class="graphic graphic_diagnosticimage graphicRef51957" href="/z/d/graphic/51957.html" rel="external">
          image 6
         </a>
         ). Blebs, seen in emphysema, are thinner walled and not accompanied by proximal airway changes.
        </p>
        <p>
        </p>
        <p>
         Although not characteristic of bronchiectasis, other abnormalities may be seen on HRCT, none of which are diagnostic of bronchiectasis:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Consolidation of a segment or lobe (from pneumonia).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Enlarged lymph nodes, likely a reaction to infection.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Areas of low attenuation and vascular disruption (mosaic pattern). This is probably due to the distorting effect of an inflammatory process in small airways.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h3">
          Distribution
         </span>
         <span class="headingEndMark">
          —
         </span>
         The distribution of bronchiectasis may be important diagnostically. A central (perihilar) distribution is suggestive of allergic bronchopulmonary aspergillosis (ABPA); predominant upper lobe distribution is characteristic of CF or one of its variants; middle and lower lobe distribution is consistent with primary ciliary dyskinesia (PCD); middle lobe and lingular segment of the left upper lobe involvement is characteristic of NTM; and lower lobe involvement is typical of idiopathic bronchiectasis [
         <a href="#rid113">
          113-116
         </a>
         ]  (
         <a class="graphic graphic_diagnosticimage graphicRef64077 graphicRef53471 graphicRef78762" href="/z/d/graphic/64077.html" rel="external">
          image 7A-C
         </a>
         ).
        </p>
        <p>
         Another confounding diagnosis is the "traction bronchiectasis" seen in pulmonary fibrosis  (
         <a class="graphic graphic_diagnosticimage graphicRef70396" href="/z/d/graphic/70396.html" rel="external">
          image 8
         </a>
         ). When the lung parenchyma is distorted by fibrosis, the airways can be dilated or pulled to simulate bronchiectasis; in this setting, however, the other features of bronchiectasis are absent.
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h3">
          Severity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Various grading or scoring systems have been proposed to correlate the extent of bronchiectasis on HRCT with disease severity; however, none of these systems has been validated prospectively or with large patient populations [
         <a href="#rid117">
          117-120
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One group performed serial HRCTs and spirometry on 48 patients with bronchiectasis, with follow-up ranging from 6 to 74 months [
         <a href="#rid118">
          118
         </a>
         ]. HRCT evidence of mucous plugging (potentially reversible) and bronchial wall thickening best correlated with decline in forced expiratory volume in one second (FEV
         <sub>
          1
         </sub>
         ) and forced vital capacity (FVC).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among patients with COPD, coexisting MDCT evidence of bronchiectasis is associated with increased severity of COPD exacerbations. In a two-year follow-up study of 54 patients with stable COPD, 27 patients (50 percent) had coexisting lower lobe bronchiectasis [
         <a href="#rid120">
          120
         </a>
         ]. Compared with patients without bronchiectasis, patients with bronchiectasis had a longer duration of symptoms during exacerbations, a greater burden of potentially pathogenic bacteria in the lower airway, and increased sputum inflammatory markers, including interleukin (IL)-8 and IL-6 [
         <a href="#rid120">
          120
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the largest of this type of study, bronchiectasis severity on HRCT scans was studied in 184 patients from Scotland [
         <a href="#rid121">
          121
         </a>
         ]. The degree of bronchial dilatation and number of segments with emphysema (adapted from the Bhalla scoring system used in CF) correlated with clinical parameters of severity including FEV
         <sub>
          1
         </sub>
         percent predicted, sputum purulence, and hospitalizations for exacerbations. The radiologic scoring system was then validated in 302 patients from six bronchiectasis centers in Great Britain and Europe. Simplified HRCT scoring systems in combination with clinical parameters may help predict disease severity.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h2">
          Lung function tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pulmonary function testing is used for functional assessment of impairment due to bronchiectasis. Spirometry before and after the administration of a bronchodilator is satisfactory in most patients. Obstructive impairment (ie, reduced or normal FVC, low FEV
         <sub>
          1
         </sub>
         , and low FEV
         <sub>
          1
         </sub>
         /FVC) is the most frequent finding, but a low FVC may indicate air trapping with lung volumes needed to confirm a high residual volume (RV) and high RV/TLC [
         <a href="#rid122">
          122
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6969.html" rel="external">
          "Overview of pulmonary function testing in adults"
         </a>
         .)
        </p>
        <p>
         The six-minute walk and incremental shuttle walk tests [
         <a href="#rid123">
          123
         </a>
         ] may provide additional information to spirometry (eg, FEV
         <sub>
          1
         </sub>
         ) [
         <a href="#rid124">
          124
         </a>
         ]. In a study of 27 patients with bronchiectasis, the six-minute walk test distance correlated more closely with quality of life (St. George Respiratory Questionnaire and Short Form 36) than the physiologic tests [
         <a href="#rid125">
          125
         </a>
         ].
        </p>
        <p>
         The Lung Clearance Index (LCI; multiple breath washout) is another method to measure airflow limitation, but it is only available in specialized laboratories. In bronchiectasis, the LCI is reproducible, may be more sensitive than the FEV
         <sub>
          1
         </sub>
         , and correlates better with CT abnormalities than FEV
         <sub>
          1
         </sub>
         [
         <a href="#rid126">
          126
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6369.html" rel="external">
          "Cystic fibrosis: Clinical manifestations of pulmonary disease", section on 'Pulmonary function testing'
         </a>
         .)
        </p>
        <p>
         Impulse oscillometry is a technique that uses pressure oscillations generated at the mouth to assess airway resistance. In a study of 100 patients with bronchiectasis, impulse oscillometry measures of airway resistance correlated with mild impairment as judged by low HRCT scores, suggesting this test may be a better index of early or mild bronchiectasis than FEV
         <sub>
          1
         </sub>
         . Impulse oscillometry did not correlate with exacerbations or more severe impairment [
         <a href="#rid127">
          127
         </a>
         ]. Further study is needed before this technique is incorporated into routine assessment of bronchiectasis.
        </p>
        <p>
         One analysis of patients with bronchiectasis followed every four months for a year found that FEV
         <sub>
          1
         </sub>
         and certain health-associated quality-of-life measures had low variability in patients with clinically stable disease, making them amenable to follow longitudinally in both clinical and research settings [
         <a href="#rid128">
          128
         </a>
         ]. LCI and C-reactive protein showed greater test-to-test variability than these other measures.
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h2">
          Other studies
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients suspected of having primary ciliary dyskinesia, the history will dictate what tests will help confirm the diagnosis (eg, family history, infertility, situs inversus) [
         <a href="#rid59">
          59,129
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4338.html" rel="external">
          "Primary ciliary dyskinesia (immotile-cilia syndrome)", section on 'Diagnostic evaluation'
         </a>
         .)
        </p>
        <p>
         Flexible bronchoscopy may be needed when sputum studies are negative and mycobacteria or a focal obstructing lesion are suspected. (See
         <a class="local">
          'Airway obstruction'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H893781857">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of bronchiectasis is based on a combination of clinical and CT features [
         <a href="#rid1">
          1,94
         </a>
         ]. Clinical features indicative of clinically significant bronchiectasis include cough on most days of the week, sputum production on most days of the week, and a history of exacerbations (see
         <a class="local">
          'Clinical features'
         </a>
         above). CT features that are reliable signs of bronchiectasis include the following (see
         <a class="local">
          'Computed tomography'
         </a>
         above):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Airway-to-arterial ratio ≥1.5 (internal airway lumen diameter/adjacent pulmonary artery diameter)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lack of tapering of bronchi (tram track appearance)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Airway visibility within 1 cm of a costal pleural surface or touching the mediastinal pleura
        </p>
        <p>
        </p>
        <p>
         Once a diagnosis of bronchiectasis is made, efforts should be directed at determining the underlying cause  (
         <a class="graphic graphic_table graphicRef56821" href="/z/d/graphic/56821.html" rel="external">
          table 1A
         </a>
         and
         <a class="graphic graphic_table graphicRef69598" href="/z/d/graphic/69598.html" rel="external">
          table 1B
         </a>
         and
         <a class="graphic graphic_table graphicRef81561" href="/z/d/graphic/81561.html" rel="external">
          table 1C
         </a>
         ). (See
         <a class="local">
          'Etiologies'
         </a>
         above and
         <a class="local">
          'Laboratory tests'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h1">
          BRONCHIECTASIS REGISTRIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Research registries in the United States, Europe, and the United Kingdom have been established to gather key patient-related diagnostic and therapeutic features. These registries are available for multicenter research studies [
         <a href="#rid76">
          76,130-132
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H600223631">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/116208.html" rel="external">
          "Society guideline links: Bronchiectasis"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/122199.html" rel="external">
          "Society guideline links: Primary ciliary dyskinesia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H81824233">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/83427.html" rel="external">
          "Patient education: Allergic bronchopulmonary aspergillosis (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/16905.html" rel="external">
          "Patient education: Coughing up blood (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/86554.html" rel="external">
          "Patient education: Bronchiectasis in adults (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H26">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathophysiology
         </strong>
         – Bronchiectasis is an acquired disorder of the major bronchi and bronchioles that is characterized by permanent abnormal dilatation and destruction of bronchial walls. The induction of bronchiectasis requires an infectious insult plus impairment of drainage, airway obstruction, and/or a defect in host defense. (See
         <a class="local">
          'Pathophysiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Causes
         </strong>
         – There are numerous etiologies that can induce or contribute to the pathophysiologic processes that result in bronchiectasis. They include airway obstruction (eg, foreign body aspiration), defective host defenses, cystic fibrosis (CF), rheumatic and systemic diseases, dyskinetic cilia, pulmonary infections, and allergic bronchopulmonary aspergillosis (ABPA). (See
         <a class="local">
          'Etiologies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
         – The classic clinical manifestations of bronchiectasis are cough on most days of the week, daily production of mucopurulent and tenacious sputum for months to years, and a history of exacerbations. Less specific complaints include dyspnea, hemoptysis, wheezing, and pleuritic chest pain. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation
         </strong>
         – The purpose of the diagnostic evaluation is confirmation of the diagnosis on chest imaging, identification of potentially treatable causes, and functional assessment. The evaluation consists of laboratory and microbiologic testing, radiographic imaging, and pulmonary function testing  (
         <a class="graphic graphic_table graphicRef56821 graphicRef69598 graphicRef81561" href="/z/d/graphic/56821.html" rel="external">
          table 1A-C
         </a>
         ). (See
         <a class="local">
          'Diagnostic evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The initial evaluation of a patient with bronchiectasis should include a complete blood count with differential, immunoglobulin quantitation (IgG, IgM, and IgA), and sputum culture and smear for bacteria, mycobacteria, and fungi. (See
         <a class="local">
          'Laboratory tests'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Imaging
         </strong>
         – The chest radiograph is abnormal in most patients with bronchiectasis. However, CT of the chest is the defining test of bronchiectasis. Characteristic CT features of bronchiectasis include airway dilatation (airway lumen-artery diameter ratio ≥1.5), lack of airway tapering (parallel or "tram" line appearance), and airway visibility at the lung periphery. Bronchial wall thickening, cystic dilation of bronchi, and mucopurulent plugs or debris accompanied by air trapping may be observed. (See
         <a class="local">
          'Chest radiograph'
         </a>
         above and
         <a class="local">
          'Computed tomography'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pulmonary function testing
         </strong>
         – Pulmonary function testing is used for functional assessment of impairment due to bronchiectasis. Obstructive impairment (ie, reduced or normal forced vital capacity [FVC], low forced expiratory volume in one second [FEV
         <sub>
          1
         </sub>
         ], and low FEV
         <sub>
          1
         </sub>
         /FVC) is the most frequent finding. (See
         <a class="local">
          'Lung function tests'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – The diagnosis of bronchiectasis is established based on the combination of typical clinical features and characteristic CT features of bronchial airway dilatation. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bronchiectasis registries
         </strong>
         – Bronchiectasis research consortia and registries have been established to gather key patient-related diagnostic and therapeutic features. (See
         <a class="local">
          'Bronchiectasis registries'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Aliberti S, Goeminne PC, O'Donnell AE, et al. Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations. Lancet Respir Med 2022; 10:298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weycker D, Hansen GL, Seifer FD. Prevalence and incidence of noncystic fibrosis bronchiectasis among US adults in 2013. Chron Respir Dis 2017; 14:377.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henkle E, Chan B, Curtis JR, et al. Characteristics and Health-care Utilization History of Patients With Bronchiectasis in US Medicare Enrollees With Prescription Drug Plans, 2006 to 2014. Chest 2018; 154:1311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quint JK, Millett ER, Joshi M, et al. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study. Eur Respir J 2016; 47:186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ringshausen FC, Rademacher J, Pink I, et al. Increasing bronchiectasis prevalence in Germany, 2009-2017: a population-based cohort study. Eur Respir J 2019; 54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Çolak Y, Nordestgaard BG, Laursen LC, et al. Risk Factors for Chronic Cough Among 14,669 Individuals From the General Population. Chest 2017; 152:563.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roberts JM, Goyal V, Kularatna S, et al. The Economic Burden of Bronchiectasis: A Systematic Review. Chest 2023; 164:1396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCallum GB, Singleton RJ, Redding GJ, et al. A decade on: Follow-up findings of indigenous children with bronchiectasis. Pediatr Pulmonol 2020; 55:975.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blackall SR, Hong JB, King P, et al. Bronchiectasis in indigenous and non-indigenous residents of Australia and New Zealand. Respirology 2018; 23:743.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chalmers JD, Hill AT. Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis. Mol Immunol 2013; 55:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bedi P, Davidson DJ, McHugh BJ, et al. Blood Neutrophils Are Reprogrammed in Bronchiectasis. Am J Respir Crit Care Med 2018; 198:880.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Finch S, Shoemark A, Dicker AJ, et al. Pregnancy Zone Protein Is Associated with Airway Infection, Neutrophil Extracellular Trap Formation, and Disease Severity in Bronchiectasis. Am J Respir Crit Care Med 2019; 200:992.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keir HR, Shoemark A, Dicker AJ, et al. Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study. Lancet Respir Med 2021; 9:873.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramsey KA, Chen ACH, Radicioni G, et al. Airway Mucus Hyperconcentration in Non-Cystic Fibrosis Bronchiectasis. Am J Respir Crit Care Med 2020; 201:661.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Redding GJ, Kishioka C, Martinez P, Rubin BK. Physical and transport properties of sputum from children with idiopathic bronchiectasis. Chest 2008; 134:1129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Asakura T, Okuda K, Chen G, et al. Proximal and Distal Bronchioles Contribute to the Pathogenesis of Non-Cystic Fibrosis Bronchiectasis (NCFB). Am J Respir Crit Care Med 2023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mac Aogáin M, Tiew PY, Lim AYH, et al. Distinct "Immunoallertypes" of Disease and High Frequencies of Sensitization in Non-Cystic Fibrosis Bronchiectasis. Am J Respir Crit Care Med 2019; 199:842.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bienvenu T, Sermet-Gaudelus I, Burgel PR, et al. Cystic fibrosis transmembrane conductance regulator channel dysfunction in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2010; 181:1078.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chalmers JD, McHugh BJ, Docherty C, et al. Vitamin-D deficiency is associated with chronic bacterial colonisation and disease severity in bronchiectasis. Thorax 2013; 68:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van de Ven AA, van Montfrans JM, Terheggen-Lagro SW, et al. A CT scan score for the assessment of lung disease in children with common variable immunodeficiency disorders. Chest 2010; 138:371.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McShane PJ, Naureckas ET, Strek ME. Bronchiectasis in a diverse US population: effects of ethnicity on etiology and sputum culture. Chest 2012; 142:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anwar GA, McDonnell MJ, Worthy SA, et al. Phenotyping adults with non-cystic fibrosis bronchiectasis: a prospective observational cohort study. Respir Med 2013; 107:1001.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Araújo D, Shteinberg M, Aliberti S, et al. Standardised classification of the aetiology of bronchiectasis using an objective algorithm. Eur Respir J 2017; 50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chalmers JD, Polverino E, Crichton ML, et al. Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC). Lancet Respir Med 2023; 11:637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pasteur MC, Bilton D, Hill AT, British Thoracic Society Bronchiectasis non-CF Guideline Group. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010; 65 Suppl 1:i1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brower KS, Del Vecchio MT, Aronoff SC. The etiologies of non-CF bronchiectasis in childhood: a systematic review of 989 subjects. BMC Pediatr 2014; 14:4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kwon KY, Myers JL, Swensen SJ, Colby TV. Middle lobe syndrome: a clinicopathological study of 21 patients. Hum Pathol 1995; 26:302.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Debray MP, Marceau A, Dombret MC, et al. Bronchiectasis Complicating Lung Volume Reduction Coil Treatment. Chest 2017; 152:e57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piccione JC, McPhail GL, Fenchel MC, et al. Bronchiectasis in chronic pulmonary aspiration: risk factors and clinical implications. Pediatr Pulmonol 2012; 47:447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Priftis KN, Mermiri D, Papadopoulou A, et al. The role of timely intervention in middle lobe syndrome in children. Chest 2005; 128:2504.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDonnell MJ, O'Toole D, Ward C, et al. A qualitative synthesis of gastro-oesophageal reflux in bronchiectasis: Current understanding and future risk. Respir Med 2018; 141:132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Noriega Aldave AP, William Saliski D. The clinical manifestations, diagnosis and management of williams-campbell syndrome. N Am J Med Sci 2014; 6:429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krustins E, Kravale Z, Buls A. Mounier-Kuhn syndrome or congenital tracheobronchomegaly: a literature review. Respir Med 2013; 107:1822.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knowles MR, Daniels LA, Davis SD, et al. Primary ciliary dyskinesia. Recent advances in diagnostics, genetics, and characterization of clinical disease. Am J Respir Crit Care Med 2013; 188:913.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rook M, Postma DS, van der Jagt EJ, et al. Mycophenolate mofetil and bronchiectasis in kidney transplant patients: a possible relationship. Transplantation 2006; 81:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rentenaar RJ, van Diepen FN, Meijer RT, et al. Immune responsiveness in renal transplant recipients: mycophenolic acid severely depresses humoral immunity in vivo. Kidney Int 2002; 62:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Geri G, Dadoun S, Bui T, et al. Risk of infections in bronchiectasis during disease-modifying treatment and biologics for rheumatic diseases. BMC Infect Dis 2011; 11:304.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shillitoe B, Gennery A. X-Linked Agammaglobulinaemia: Outcomes in the modern era. Clin Immunol 2017; 183:54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gathmann B, Mahlaoui N, CEREDIH, et al. Clinical picture and treatment of 2212 patients with common variable immunodeficiency. J Allergy Clin Immunol 2014; 134:116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelesidis T, Yang O. Good's syndrome remains a mystery after 55 years: A systematic review of the scientific evidence. Clin Immunol 2010; 135:347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schatorjé EJ, de Jong E, van Hout RW, et al. The Challenge of Immunoglobulin-G Subclass Deficiency and Specific Polysaccharide Antibody Deficiency--a Dutch Pediatric Cohort Study. J Clin Immunol 2016; 36:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vendrell M, de Gracia J, Rodrigo MJ, et al. Antibody production deficiency with normal IgG levels in bronchiectasis of unknown etiology. Chest 2005; 127:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Kessel DA, van Velzen-Blad H, van den Bosch JM, Rijkers GT. Impaired pneumococcal antibody response in bronchiectasis of unknown aetiology. Eur Respir J 2005; 25:482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farrell PM, White TB, Ren CL, et al. Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation. J Pediatr 2017; 181S:S4.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Keating CL, Liu X, Dimango EA. Classic respiratory disease but atypical diagnostic testing distinguishes adult presentation of cystic fibrosis. Chest 2010; 137:1157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodman DM, Polis JM, Heltshe SL, et al. Late diagnosis defines a unique population of long-term survivors of cystic fibrosis. Am J Respir Crit Care Med 2005; 171:621.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ziedalski TM, Kao PN, Henig NR, et al. Prospective analysis of cystic fibrosis transmembrane regulator mutations in adults with bronchiectasis or pulmonary nontuberculous mycobacterial infection. Chest 2006; 130:995.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Çolak Y, Nordestgaard BG, Afzal S. Morbidity and mortality in carriers of the cystic fibrosis mutation CFTR Phe508del in the general population. Eur Respir J 2020; 56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martin C, Burgel PR. Carriers of a single CFTR mutation are asymptomatic: an evolving dogma? Eur Respir J 2020; 56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hendry WF, A'Hern RP, Cole PJ. Was Young's syndrome caused by exposure to mercury in childhood? BMJ 1993; 307:1579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demoruelle MK, Weisman MH, Simonian PL, et al. Brief report: airways abnormalities and rheumatoid arthritis-related autoantibodies in subjects without arthritis: early injury or initiating site of autoimmunity? Arthritis Rheum 2012; 64:1756.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perry E, Stenton C, Kelly C, et al. RA autoantibodies as predictors of rheumatoid arthritis in non-cystic fibrosis bronchiectasis patients. Eur Respir J 2014; 44:1082.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilczynska MM, Condliffe AM, McKeon DJ. Coexistence of bronchiectasis and rheumatoid arthritis: revisited. Respir Care 2013; 58:694.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soto-Cardenas MJ, Perez-De-Lis M, Bove A, et al. Bronchiectasis in primary Sjögren's syndrome: prevalence and clinical significance. Clin Exp Rheumatol 2010; 28:647.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Soyza A, McDonnell MJ, Goeminne PC, et al. Bronchiectasis Rheumatoid overlap syndrome (BROS) is an independent risk factor for mortality in patients with bronchiectasis: A multicentre cohort study. Chest 2017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Puéchal X, Bienvenu T, Génin E, et al. Mutations of the cystic fibrosis gene in patients with bronchiectasis associated with rheumatoid arthritis. Ann Rheum Dis 2011; 70:653.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woodfield G, Nisbet M, Jacob J, et al. Bronchiectasis in yellow nail syndrome. Respirology 2017; 22:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Camus P, Colby TV. The Spectrum of Airway Involvement in Inflammatory Bowel Disease. Clin Chest Med 2022; 43:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leigh MW, Ferkol TW, Davis SD, et al. Clinical Features and Associated Likelihood of Primary Ciliary Dyskinesia in Children and Adolescents. Ann Am Thorac Soc 2016; 13:1305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wee WB, Kaspy KR, Sawras MG, et al. Going beyond the chest X-ray: Investigating laterality defects in primary ciliary dyskinesia. Pediatr Pulmonol 2022; 57:1318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shapiro AJ, Dell SD, Gaston B, et al. Nasal Nitric Oxide Measurement in Primary Ciliary Dyskinesia. A Technical Paper on Standardized Testing Protocols. Ann Am Thorac Soc 2020; 17:e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shapiro AJ, Davis SD, Polineni D, et al. Diagnosis of Primary Ciliary Dyskinesia. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 2018; 197:e24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shoemark A, Griffin H, Wheway G, et al. Genome sequencing reveals underdiagnosis of primary ciliary dyskinesia in bronchiectasis. Eur Respir J 2022; 60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Driscoll JA, Bhalla S, Liapis H, et al. Autosomal dominant polycystic kidney disease is associated with an increased prevalence of radiographic bronchiectasis. Chest 2008; 133:1181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moua T, Zand L, Hartman RP, et al. Radiologic and clinical bronchiectasis associated with autosomal dominant polycystic kidney disease. PLoS One 2014; 9:e93674.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parr DG, Guest PG, Reynolds JH, et al. Prevalence and impact of bronchiectasis in alpha1-antitrypsin deficiency. Am J Respir Crit Care Med 2007; 176:1215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sandhaus RA, Turino G, Brantly ML, et al. The Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in the Adult. Chronic Obstr Pulm Dis 2016; 3:668.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim CK, Chung CY, Kim JS, et al. Late abnormal findings on high-resolution computed tomography after Mycoplasma pneumonia. Pediatrics 2000; 105:372.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wurzel DF, Marchant JM, Yerkovich ST, et al. Protracted Bacterial Bronchitis in Children: Natural History and Risk Factors for Bronchiectasis. Chest 2016; 150:1101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mossman AK, Svishchuk J, Waddell BJM, et al. Staphylococcus aureus in Non-Cystic Fibrosis Bronchiectasis: Prevalence and Genomic Basis of High Inoculum β-Lactam Resistance. Ann Am Thorac Soc 2022; 19:1285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gilmartin M, Basirat A, Barry C, et al. Rapid-Onset Cystic Bronchiectasis in a Mechanically Ventilated Patient with COVID-19. Am J Respir Crit Care Med 2022; 205:721.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martinez-Garcia MA, Aksamit TR, Aliberti S. Bronchiectasis as a Long-Term Consequence of SARS-COVID-19 Pneumonia: Future Studies are Needed. Arch Bronconeumol 2021; 57:739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           José RJ, Manuel A, Gibson-Bailey K, Lee L. Post COVID-19 bronchiectasis: a potential epidemic within a pandemic. Expert Rev Respir Med 2020; 14:1183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kwak HJ, Moon JY, Choi YW, et al. High prevalence of bronchiectasis in adults: analysis of CT findings in a health screening program. Tohoku J Exp Med 2010; 222:237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dimakou K, Triantafillidou C, Toumbis M, et al. Non CF-bronchiectasis: Aetiologic approach, clinical, radiological, microbiological and functional profile in 277 patients. Respir Med 2016; 116:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aksamit TR, O'Donnell AE, Barker A, et al. Adult Patients With Bronchiectasis: A First Look at the US Bronchiectasis Research Registry. Chest 2017; 151:982.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prevots DR, Marras TK. Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review. Clin Chest Med 2015; 36:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Szymanski EP, Leung JM, Fowler CJ, et al. Pulmonary Nontuberculous Mycobacterial Infection. A Multisystem, Multigenic Disease. Am J Respir Crit Care Med 2015; 192:618.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kunst H, Wickremasinghe M, Wells A, Wilson R. Nontuberculous mycobacterial disease and Aspergillus-related lung disease in bronchiectasis. Eur Respir J 2006; 28:352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fujita J, Ohtsuki Y, Shigeto E, et al. Pathological findings of bronchiectases caused by Mycobacterium avium intracellulare complex. Respir Med 2003; 97:933.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woodworth MH, Saullo JL, Lantos PM, et al. Increasing Nocardia Incidence Associated with Bronchiectasis at a Tertiary Care Center. Ann Am Thorac Soc 2017; 14:347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tiew PY, Lim AYH, Keir HR, et al. High Frequency of Allergic Bronchopulmonary Aspergillosis in Bronchiectasis-COPD Overlap. Chest 2022; 161:40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Agarwal R, Muthu V, Sehgal IS, et al. Allergic Bronchopulmonary Aspergillosis. Clin Chest Med 2022; 43:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mao B, Yang JW, Lu HW, Xu JF. Asthma and bronchiectasis exacerbation. Eur Respir J 2016; 47:1680.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chaudhuri R, Rubin A, Sumino K, et al. Safety and effectiveness of bronchial thermoplasty after 10 years in patients with persistent asthma (BT10+): a follow-up of three randomised controlled trials. Lancet Respir Med 2021; 9:457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martínez-García MA, de la Rosa Carrillo D, Soler-Cataluña JJ, et al. Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187:823.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goeminne PC, Nawrot TS, Ruttens D, et al. Mortality in non-cystic fibrosis bronchiectasis: a prospective cohort analysis. Respir Med 2014; 108:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hurst JR, Elborn JS, De Soyza A, BRONCH-UK Consortium. COPD-bronchiectasis overlap syndrome. Eur Respir J 2015; 45:310.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang JT, Cant E, Keir HR, et al. Endotyping Chronic Obstructive Pulmonary Disease, Bronchiectasis, and the "Chronic Obstructive Pulmonary Disease-Bronchiectasis Association". Am J Respir Crit Care Med 2022; 206:417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Du Q, Jin J, Liu X, Sun Y. Bronchiectasis as a Comorbidity of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis. PLoS One 2016; 11:e0150532.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Traversi L, Miravitlles M, Martinez-Garcia MA, et al. ROSE: radiology, obstruction, symptoms and exposure - a Delphi consensus definition of the association of COPD and bronchiectasis by the EMBARC Airways Working Group. ERJ Open Res 2021; 7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diaz AA, Wang W, Orejas JL, et al. Suspected Bronchiectasis and Mortality in Adults With a History of Smoking Who Have Normal and Impaired Lung Function : A Cohort Study. Ann Intern Med 2023; 176:1340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diaz AA, Young TP, Maselli DJ, et al. Quantitative CT Measures of Bronchiectasis in Smokers. Chest 2017; 151:1255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hill AT, Sullivan AL, Chalmers JD, et al. British Thoracic Society Guideline for bronchiectasis in adults. Thorax 2019; 74:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mac Aogáin M, Chotirmall SH. Bronchiectasis and cough: An old relationship in need of renewed attention. Pulm Pharmacol Ther 2019; 57:101812.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           King PT, Holdsworth SR, Freezer NJ, et al. Characterisation of the onset and presenting clinical features of adult bronchiectasis. Respir Med 2006; 100:2183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McLeese RH, Spinou A, Alfahl Z, et al. Psychometrics of health-related quality of life questionnaires in bronchiectasis: a systematic review and meta-analysis. Eur Respir J 2021; 58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lanza FC, Castro RAS, de Camargo AA, et al. COPD Assessment Test (CAT) is a Valid and Simple Tool to Measure the Impact of Bronchiectasis on Affected Patients. COPD 2018; 15:512.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Finch S, Laska IF, Abo-Leyah H, et al. Validation of the COPD Assessment Test (CAT) as an Outcome Measure in Bronchiectasis. Chest 2020; 157:815.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De la Rosa Carrillo D, Olveira C, García-Clemente M, et al. COPD Assessment Test in Bronchiectasis: Minimum Clinically Important Difference and Psychometric Validation: A Prospective Study. Chest 2020; 157:824.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hester KL, Macfarlane JG, Tedd H, et al. Fatigue in bronchiectasis. QJM 2012; 105:235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prys-Picard CO, Niven R. Urinary incontinence in patients with bronchiectasis. Eur Respir J 2006; 27:866.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rees J, Tedd H, De Soyza A. Managing urinary incontinence in adults with bronchiectasis. Br J Nurs 2013; 22:S15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guilemany JM, Mariño-Sánchez FS, Angrill J, et al. The importance of smell in patients with bronchiectasis. Respir Med 2011; 105:44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Contreras-Bolívar V, Olveira G, Porras N, et al. Osteopenia and Osteoporosis in Patients with Bronchiectasis: Association with Respiratory Parameters, Body Composition, Muscle Strength and Bone Remodeling Biomarkers. Sci Rep 2019; 9:14496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J 2017; 50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aliberti S, Sotgiu G, Gramegna A, et al. Thrombocytosis during Stable State Predicts Mortality in Bronchiectasis. Ann Am Thorac Soc 2021; 18:1316.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shoemark A, Shteinberg M, De Soyza A, et al. Characterization of Eosinophilic Bronchiectasis: A European Multicohort Study. Am J Respir Crit Care Med 2022; 205:894.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh D, Brightling C. Bronchiectasis, the Latest Eosinophilic Airway Disease: What About the Microbiome? Am J Respir Crit Care Med 2022; 205:860.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drost N, D'silva L, Rebello R, et al. Persistent sputum cellularity and neutrophils may predict bronchiectasis. Can Respir J 2011; 18:221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Milliron B, Henry TS, Veeraraghavan S, Little BP. Bronchiectasis: Mechanisms and Imaging Clues of Associated Common and Uncommon Diseases. Radiographics 2015; 35:1011.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller WT Jr, Panosian JS. Causes and imaging patterns of tree-in-bud opacities. Chest 2013; 144:1883.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim RD, Greenberg DE, Ehrmantraut ME, et al. Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med 2008; 178:1066.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kennedy MP, Noone PG, Leigh MW, et al. High-resolution CT of patients with primary ciliary dyskinesia. AJR Am J Roentgenol 2007; 188:1232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santamaria F, Montella S, Tiddens HAWM, et al. Structural and functional lung disease in primary ciliary dyskinesia. Chest 2008; 134:351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cartier Y, Kavanagh PV, Johkoh T, et al. Bronchiectasis: accuracy of high-resolution CT in the differentiation of specific diseases. AJR Am J Roentgenol 1999; 173:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lynch DA, Newell J, Hale V, et al. Correlation of CT findings with clinical evaluations in 261 patients with symptomatic bronchiectasis. AJR Am J Roentgenol 1999; 173:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sheehan RE, Wells AU, Copley SJ, et al. A comparison of serial computed tomography and functional change in bronchiectasis. Eur Respir J 2002; 20:581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eshed I, Minski I, Katz R, et al. Bronchiectasis: correlation of high-resolution CT findings with health-related quality of life. Clin Radiol 2007; 62:152.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel IS, Vlahos I, Wilkinson TM, et al. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170:400.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bedi P, Chalmers JD, Goeminne PC, et al. The BRICS (Bronchiectasis Radiologically Indexed CT Score): A Multicenter Study Score for Use in Idiopathic and Postinfective Bronchiectasis. Chest 2018; 153:1177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Radovanovic D, Santus P, Blasi F, et al. A comprehensive approach to lung function in bronchiectasis. Respir Med 2018; 145:120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cartlidge MK, Smith MP, Bedi P, et al. Validation of the Incremental Shuttle Walk Test as a Clinical End Point in Bronchiectasis. Chest 2018; 154:1321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee AL, Hill CJ, Cecins N, et al. Minimal important difference in field walking tests in non-cystic fibrosis bronchiectasis following exercise training. Respir Med 2014; 108:1303.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee AL, Button BM, Ellis S, et al. Clinical determinants of the 6-Minute Walk Test in bronchiectasis. Respir Med 2009; 103:780.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Neill K, Lakshmipathy GR, Neely C, et al. Multiple-Breath Washout Outcome Measures in Adults with Bronchiectasis. Ann Am Thorac Soc 2022; 19:1489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guan WJ, Gao YH, Xu G, et al. Impulse oscillometry in adults with bronchiectasis. Ann Am Thorac Soc 2015; 12:657.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bradley JM, Ferguson K, Bailey A, et al. Clinimetric Properties of Outcome Measures in Bronchiectasis. Ann Am Thorac Soc 2023; 20:648.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Behan L, Dimitrov BD, Kuehni CE, et al. PICADAR: a diagnostic predictive tool for primary ciliary dyskinesia. Eur Respir J 2016; 47:1103.
          </a>
         </li>
         <li class="breakAll">
          Bronchiectasis Research Registry. https://www.bronchiectasisandntminitiative.org/ (Accessed on January 08, 2020).
         </li>
         <li class="breakAll">
          The European Bronchiectasis Registry. EMBARC web site. https://www.bronchiectasis.eu/ (Accessed on January 08, 2020).
         </li>
         <li class="breakAll">
          BRONCH-UK: The UK bronchiectasis network and biobank . https://www.bronch.ac.uk (Accessed on January 08, 2020).
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 1444 Version 67.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34570994" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28555504" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Prevalence and incidence of noncystic fibrosis bronchiectasis among US adults in 2013.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30055168" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Characteristics and Health-care Utilization History of Patients With Bronchiectasis in US Medicare Enrollees With Prescription Drug Plans, 2006 to 2014.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26541539" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31467114" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Increasing bronchiectasis prevalence in Germany, 2009-2017: a population-based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28625577" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Risk Factors for Chronic Cough Among 14,669 Individuals From the General Population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37423293" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : The Economic Burden of Bronchiectasis: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32096916" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : A decade on: Follow-up findings of indigenous children with bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29502335" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Bronchiectasis in indigenous and non-indigenous residents of Australia and New Zealand.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23088941" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29733693" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Blood Neutrophils Are Reprogrammed in Bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31264895" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Pregnancy Zone Protein Is Associated with Airway Infection, Neutrophil Extracellular Trap Formation, and Disease Severity in Bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33609487" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Neutrophil extracellular traps, disease severity, and antibiotic response in bronchiectasis: an international, observational, multicohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31765597" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Airway Mucus Hyperconcentration in Non-Cystic Fibrosis Bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18753467" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Physical and transport properties of sputum from children with idiopathic bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/38016030" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Proximal and Distal Bronchioles Contribute to the Pathogenesis of Non-Cystic Fibrosis Bronchiectasis (NCFB).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30265843" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Distinct "Immunoallertypes" of Disease and High Frequencies of Sensitization in Non-Cystic Fibrosis Bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20167849" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Cystic fibrosis transmembrane conductance regulator channel dysfunction in non-cystic fibrosis bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23076388" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Vitamin-D deficiency is associated with chronic bacterial colonisation and disease severity in bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20299624" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : A CT scan score for the assessment of lung disease in children with common variable immunodeficiency disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22267679" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Bronchiectasis in a diverse US population: effects of ethnicity on etiology and sputum culture.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23672995" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Phenotyping adults with non-cystic fibrosis bronchiectasis: a prospective observational cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29242262" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Standardised classification of the aetiology of bronchiectasis using an objective algorithm.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37105206" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20627931" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : British Thoracic Society guideline for non-CF bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25492164" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : The etiologies of non-CF bronchiectasis in childhood: a systematic review of 989 subjects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7890282" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Middle lobe syndrome: a clinicopathological study of 21 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28889896" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Bronchiectasis Complicating Lung Volume Reduction Coil Treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22028069" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Bronchiectasis in chronic pulmonary aspiration: risk factors and clinical implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16236916" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : The role of timely intervention in middle lobe syndrome in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30053958" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : A qualitative synthesis of gastro-oesophageal reflux in bronchiectasis: Current understanding and future risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25317385" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : The clinical manifestations, diagnosis and management of williams-campbell syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24070565" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Mounier-Kuhn syndrome or congenital tracheobronchomegaly: a literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23796196" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Primary ciliary dyskinesia. Recent advances in diagnostics, genetics, and characterization of clinical disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16436974" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Mycophenolate mofetil and bronchiectasis in kidney transplant patients: a possible relationship.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12081594" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Immune responsiveness in renal transplant recipients: mycophenolic acid severely depresses humoral immunity in vivo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22046967" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Risk of infections in bronchiectasis during disease-modifying treatment and biologics for rheumatic diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28729230" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : X-Linked Agammaglobulinaemia: Outcomes in the modern era.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24582312" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Clinical picture and treatment of 2212 patients with common variable immunodeficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20149753" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Good's syndrome remains a mystery after 55 years: A systematic review of the scientific evidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26846287" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : The Challenge of Immunoglobulin-G Subclass Deficiency and Specific Polysaccharide Antibody Deficiency--a Dutch Pediatric Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15653984" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Antibody production deficiency with normal IgG levels in bronchiectasis of unknown etiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15738292" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Impaired pneumococcal antibody response in bronchiectasis of unknown aetiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28129811" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19965956" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Classic respiratory disease but atypical diagnostic testing distinguishes adult presentation of cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15591474" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Late diagnosis defines a unique population of long-term survivors of cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17035430" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Prospective analysis of cystic fibrosis transmembrane regulator mutations in adults with bronchiectasis or pulmonary nontuberculous mycobacterial infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32398304" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Morbidity and mortality in carriers of the cystic fibrosis mutation CFTR Phe508del in the general population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32912926" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Carriers of a single CFTR mutation are asymptomatic: an evolving dogma?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8292944" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Was Young's syndrome caused by exposure to mercury in childhood?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22183986" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Brief report: airways abnormalities and rheumatoid arthritis-related autoantibodies in subjects without arthritis: early injury or initiating site of autoimmunity?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24969651" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : RA autoantibodies as predictors of rheumatoid arthritis in non-cystic fibrosis bronchiectasis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22782500" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Coexistence of bronchiectasis and rheumatoid arthritis: revisited.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20883638" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Bronchiectasis in primary Sjögren's syndrome: prevalence and clinical significance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28093268" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Bronchiectasis Rheumatoid overlap syndrome (BROS) is an independent risk factor for mortality in patients with bronchiectasis: A multicentre cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21131649" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Mutations of the cystic fibrosis gene in patients with bronchiectasis associated with rheumatoid arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27551950" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Bronchiectasis in yellow nail syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35236554" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : The Spectrum of Airway Involvement in Inflammatory Bowel Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27070726" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Clinical Features and Associated Likelihood of Primary Ciliary Dyskinesia in Children and Adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35122416" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Going beyond the chest X-ray: Investigating laterality defects in primary ciliary dyskinesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31770003" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Nasal Nitric Oxide Measurement in Primary Ciliary Dyskinesia. A Technical Paper on Standardized Testing Protocols.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29905515" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Diagnosis of Primary Ciliary Dyskinesia. An Official American Thoracic Society Clinical Practice Guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35728977" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Genome sequencing reveals underdiagnosis of primary ciliary dyskinesia in bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18263686" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Autosomal dominant polycystic kidney disease is associated with an increased prevalence of radiographic bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24747723" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Radiologic and clinical bronchiectasis associated with autosomal dominant polycystic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17872489" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Prevalence and impact of bronchiectasis in alpha1-antitrypsin deficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28848891" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : The Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in the Adult.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10654958" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Late abnormal findings on high-resolution computed tomography after Mycoplasma pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27400908" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Protracted Bacterial Bronchitis in Children: Natural History and Risk Factors for Bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35213810" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Staphylococcus aureus in Non-Cystic Fibrosis Bronchiectasis: Prevalence and Genomic Basis of High Inoculumβ-Lactam Resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34982650" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Rapid-Onset Cystic Bronchiectasis in a Mechanically Ventilated Patient with COVID-19.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33994633" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Bronchiectasis as a Long-Term Consequence of SARS-COVID-19 Pneumonia: Future Studies are Needed.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33054432" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Post COVID-19 bronchiectasis: a potential epidemic within a pandemic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21127394" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : High prevalence of bronchiectasis in adults: analysis of CT findings in a health screening program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27296814" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Non CF-bronchiectasis: Aetiologic approach, clinical, radiological, microbiological and functional profile in 277 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27889361" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Adult Patients With Bronchiectasis: A First Look at the US Bronchiectasis Research Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25676516" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26038974" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Pulmonary Nontuberculous Mycobacterial Infection. A Multisystem, Multigenic Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16611651" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Nontuberculous mycobacterial disease and Aspergillus-related lung disease in bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12924521" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Pathological findings of bronchiectases caused by Mycobacterium avium intracellulare complex.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28231023" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Increasing Nocardia Incidence Associated with Bronchiectasis at a Tertiary Care Center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34364870" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : High Frequency of Allergic Bronchopulmonary Aspergillosis in Bronchiectasis-COPD Overlap.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35236565" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Allergic Bronchopulmonary Aspergillosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27076584" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Asthma and bronchiectasis exacerbation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33524320" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Safety and effectiveness of bronchial thermoplasty after 10 years in patients with persistent asthma (BT10+): a follow-up of three randomised controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23392438" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Prognostic value of bronchiectasis in patients with moderate-to-severe chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24445062" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Mortality in non-cystic fibrosis bronchiectasis: a prospective cohort analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25653262" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : COPD-bronchiectasis overlap syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35436182" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Endotyping Chronic Obstructive Pulmonary Disease, Bronchiectasis, and the "Chronic Obstructive Pulmonary Disease-Bronchiectasis Association".
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26978269" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Bronchiectasis as a Comorbidity of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34820447" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : ROSE: radiology, obstruction, symptoms and exposure - a Delphi consensus definition of the association of COPD and bronchiectasis by the EMBARC Airways Working Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37782931" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Suspected Bronchiectasis and Mortality in Adults With a History of Smoking Who Have Normal and Impaired Lung Function : A Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27890712" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Quantitative CT Measures of Bronchiectasis in Smokers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30545985" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : British Thoracic Society Guideline for bronchiectasis in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31176801" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Bronchiectasis and cough: An old relationship in need of renewed attention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16650970" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Characterisation of the onset and presenting clinical features of adult bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33888521" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Psychometrics of health-related quality of life questionnaires in bronchiectasis: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30468091" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : COPD Assessment Test (CAT) is a Valid and Simple Tool to Measure the Impact of Bronchiectasis on Affected Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31730832" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Validation of the COPD Assessment Test (CAT) as an Outcome Measure in Bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31446064" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : COPD Assessment Test in Bronchiectasis: Minimum Clinically Important Difference and Psychometric Validation: A Prospective Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22016379" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Fatigue in bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16585099" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Urinary incontinence in patients with bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23752570" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Managing urinary incontinence in adults with bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21111591" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : The importance of smell in patients with bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31601899" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Osteopenia and Osteoporosis in Patients with Bronchiectasis: Association with Respiratory Parameters, Body Composition, Muscle Strength and Bone Remodeling Biomarkers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28889110" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : European Respiratory Society guidelines for the management of adult bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33507847" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Thrombocytosis during Stable State Predicts Mortality in Bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35050830" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Characterization of Eosinophilic Bronchiectasis: A European Multicohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35213295" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Bronchiectasis, the Latest Eosinophilic Airway Disease: What About the Microbiome?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22059180" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Persistent sputum cellularity and neutrophils may predict bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26024063" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Bronchiectasis: Mechanisms and Imaging Clues of Associated Common and Uncommon Diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23948769" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Causes and imaging patterns of tree-in-bud opacities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18703788" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17449765" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : High-resolution CT of patients with primary ciliary dyskinesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18403663" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Structural and functional lung disease in primary ciliary dyskinesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10397098" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Bronchiectasis: accuracy of high-resolution CT in the differentiation of specific diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10397099" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Correlation of CT findings with clinical evaluations in 261 patients with symptomatic bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12358332" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : A comparison of serial computed tomography and functional change in bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17207698" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Bronchiectasis: correlation of high-resolution CT findings with health-related quality of life.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15130905" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29247616" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : The BRICS (Bronchiectasis Radiologically Indexed CT Score): A Multicenter Study Score for Use in Idiopathic and Postinfective Bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30509700" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : A comprehensive approach to lung function in bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30300653" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Validation of the Incremental Shuttle Walk Test as a Clinical End Point in Bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25087836" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Minimal important difference in field walking tests in non-cystic fibrosis bronchiectasis following exercise training.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19070473" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Clinical determinants of the 6-Minute Walk Test in bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35451922" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Multiple-Breath Washout Outcome Measures in Adults with Bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25654540" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Impulse oscillometry in adults with bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36548542" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Clinimetric Properties of Outcome Measures in Bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26917608" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : PICADAR: a diagnostic predictive tool for primary ciliary dyskinesia.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
